helyzet elemzés

Teva Pharmaceutical (TEVA) on Thursday reported adjusted income of $1.08 per share on revenue of $5.69 billion for the second quarter ended June 30, compared with $1.25 and $5.04 billion, respectively, for the year-earlier period. Analysts had called for adjusted earnings of $1.11 a share on $5.85 billion in sales, according to Zacks Investment Research. The generics drug giant cut its full-year earnings guidance to $4.30-$4.50 vs. the consensus for $4.88.

Azért ezek nem olyan borzalmas számok , hogy így beverjék rá!

4,3 EPS mellett ez a 30 körüli ár egyáltalán nem tűnik túlárazottnak.